A Controlled, Randomized, First-In-Human Study of AP31969 Investigating Single and Multiple Ascending Doses and the Effect of Food in Healthy Subjects

Acesion Pharma1 site in 1 country92 target enrollmentOctober 4, 2023

ConditionsHealthy Volunteers

InterventionsAP31969 Placebo

DrugsAP31969 Placebo

Overview

Phase: Phase 1
Intervention: AP31969
Conditions: Healthy Volunteers
Sponsor: Acesion Pharma
Enrollment: 92
Locations: 1
Primary Endpoint: Number of Participants who Experienced an Adverse Event
Status: Completed
Last Updated: 9 months ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials Related News

Overview

Brief Summary

The primary objective of the study is to evaluate the safety and tolerability of single doses (Part A) and multiple doses (Part B) of AP31969 in healthy participants.

Registry

clinicaltrials.gov

Start Date

October 4, 2023

End Date

March 14, 2025

Last Updated

9 months ago

Study Type

Interventional

Study Design

Sequential

Sex

All

Investigators

Sponsor

Acesion Pharma

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Age : 18 years to 55 years, inclusive, at screening.
•Weight: ≥50 kg, at screening.
•Body mass index: 18.0 kg/m\^2 to 30.0 kg/m\^2, inclusive, at screening.
•Sex : male or female; female participants may be of childbearing potential or of nonchildbearing potential (either surgically sterilized, physiologically incapable of becoming pregnant, or at least 1 year postmenopausal \[amenorrhea duration of 12 consecutive months\] and confirmed by a follicle-stimulating hormone test at screening).
•In good physical and mental health on the basis of medical history, physical examination, clinical laboratory, 12-lead electrocardiogram (ECG), and vital signs, as judged by the Investigator.
•Resting supine systolic blood pressure (BP) (average of 3 readings) between 140 and 90 mmHg (inclusive, at screening and \[each\] admission), and diastolic BP (average of 3 readings) between 90 and 50 mmHg (inclusive, at screening and \[each\] admission). If initial results do not meet these criteria, BP may be repeated if in the judgment of the Investigator there is a reason to believe the initial result is inaccurate (eg, white coat hypertension).
•Computerized (12-lead) ECG recording without signs of clinically relevant pathology and with a QT-interval with Fridericia's correction (QTcF-interval) interval between 300 and 450 ms, inclusive, at screening and (each) admission.
•Female participants must not be pregnant or lactating. Nonpregnancy will be confirmed for all female participants by a negative serum pregnancy test at screening and (each) admission.
•Female participants of childbearing potential who have a fertile male sexual partner must agree to use highly effective contraception and not donate ova from 4 weeks prior to (the first) study drug administration until 90 days after the follow-up visit.
•Male participants, if not surgically sterilized, who have a female sexual partner of childbearing potential must agree to use highly effective contraception and not donate sperm from (first) admission until 90 days after the follow-up visit.

Exclusion Criteria

•Previous participation in the current study.
•Employee of ICON or the Sponsor.
•History of relevant drug and/or food allergies.
•History of any illness or condition that, in the opinion of the Investigator, might confound the results of the study or pose an additional risk when administering the study drug to the subject (with particular focus on cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, cerebrovascular, and neurological diseases including history of syncope and/or convulsions).
•History of any major disorder capable of significantly altering the absorption, metabolism, or elimination of the study drug, constituting a risk when taking the study drug, or interfering with the interpretation of data in the opinion of the Investigator.
•Personal or first-degree relative family history of congenital long QT syndrome or sudden death.
•Presence of any signs of tremor in rest at screening or (at one of the) admission(s) to the clinical research center.
•Use of any prescribed medication within 30 days prior to (first) admission, based on Investigator's judgment. An exception is made for hormonal contraceptives, which may be used throughout the study.
•Use of any over-the-counter medication, vitamin preparations and other food supplements, or herbal medications (eg, St. John's wort) within 14 days prior to (first) admission, based on Investigator's judgment. An exception is made for acetaminophen/paracetamol, which is allowed up to 2 g/day.
•Positive screen for hepatitis B surface antigen, hepatitis C virus antibodies, or human immunodeficiency virus 1 and 2 antibodies, at screening. In case of vaccination against these diseases, inclusion is allowed.

Arms & Interventions

Part A: Single Ascending Doses

Participants will be randomized to receive a single oral dose of AP31969 or matching placebo in 1 of 5 groups. Participants in an additional food effect assessment group will be randomized to receive 2 single oral doses of AP31969 or matching placebo; 1 dose in fasted and 1 dose in fed state in a 2-period, fixed-sequence design (first fasted, then fed with at least 1 week washout between periods).

Intervention: AP31969

Part A: Single Ascending Doses

Intervention: Placebo

Part B: Multiple Ascending Doses

Participants will be randomized to receive multiple oral doses of AP31969 or matching placebo for 10 days in 1 of 4 groups.

Intervention: AP31969

Part B: Multiple Ascending Doses

Participants will be randomized to receive multiple oral doses of AP31969 or matching placebo for 10 days in 1 of 4 groups.

Intervention: Placebo

Outcomes

Primary Outcomes

Number of Participants who Experienced an Adverse Event

Time Frame: Up to a maximum of 48 days

Secondary Outcomes

Part A: Food Effect on AUC0-last of AP31969(Part A: Day 1 to Day 4 of fed and fasted treatment periods of the food effect assessment group)
Parts A and B: Maximum Observed Plasma Concentration (Cmax) of AP31969(Part A: Day 1 to Day 4; Part B: Day 1 to Day 12)
Parts A and B: Terminal Elimination Half-life of AP31969(Part A: Day 1 to Day 4; Part B: Day 1 to Day 12)
Part A: Area Under the Plasma Concentration Time Curve (AUC) from Time 0 to Time of Last Quantifiable Concentration (AUC0-last) of AP31969(Part A: Day 1 to Day 4)
Part A: AUC from Time 0 Extrapolated to Infinity (AUC0-inf) of AP31969(Part A: Day 1 to Day 4)
Part B: AUC Over a Dosing Interval Tau (AUCtau) of AP31969(Part B: Day 1 to Day 10)
Parts A and B: Time to Cmax (tmax) of AP31969(Part A: Day 1 to Day 4; Part B: Day 1 to Day 12)
Part A: Apparent Clearance of AP31969(Part A: Day 1 to Day 4)
Part B: Apparent Clearance at Steady State of AP31969(Part B: Day 1 to Day 10)
Parts A and B: Apparent Volume of Distribution at Terminal Phase of AP31969(Part A: Day 1 to Day 4; Part B: Day 1 to Day 10)
Part B: Accumulation Ratio of AP31969(Part B: Day 1 to Day 10)
Parts A and B: Dose Normalized Cmax of AP31969(Part A: Day 1 to Day 4; Part B: Day 1 to Day 10)
Part A: Dose Normalized AUC0-last of AP31969(Part A: Day 1 to Day 4)
Part A: Dose Normalized AUC0-inf of AP31969(Part A: Day 1 to Day 4)
Part B: Dose Normalized AUCtau of AP31969(Part B: Day 1 to Day 10)
Part A: Food Effect on Cmax of AP31969(Part A: Day 1 to Day 4 of fed and fasted treatment periods of the food effect assessment group)
Part A: Food Effect on AUC0-inf of AP31969(Part A: Day 1 to Day 4 of fed and fasted treatment periods of the food effect assessment group)